{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:21:41Z","timestamp":1787851301828,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100021564","name":"National Federation of French Cancer Centres","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.108324","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:32Z","timestamp":1786119332000},"page":"108324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort"],"prefix":"10.1016","volume":"11","author":[{"given":"E.","family":"Gobbini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cl\u00e9ment-Duchene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4290-5524","authenticated-orcid":false,"given":"C.","family":"Chouaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hiret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Audigier-Valette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-7876","authenticated-orcid":false,"given":"A.","family":"Bizieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8016-7956","authenticated-orcid":false,"given":"D.","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Quantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Le Guen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9727-5075","authenticated-orcid":false,"given":"A.","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Falchero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":false,"given":"J.","family":"Remon-Masip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-9425","authenticated-orcid":false,"given":"L.","family":"Bosquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"P\u00e9rol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.108324_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70608","article-title":"Trends in the incidence and survival outcomes in patients with small cell lung cancer in the United States: an analysis of the SEER database","volume":"14","author":"Uprety","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2026.108324_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107924","article-title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the phase III IMpower133 study and the phase III IMbrella A extension study","volume":"196","author":"Reck","year":"2024","journal-title":"Lung Cancer"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108324_bib3","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108324_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108324_bib5","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1007\/s12325-021-01909-1","article-title":"Advances in treatment of recurrent small cell lung cancer (SCLC): insights for optimizing patient outcomes from an expert roundtable discussion","volume":"38","author":"Das","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.esmoop.2026.108324_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107887","article-title":"Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients: a large French multicenter study","volume":"194","author":"Pons-Tostivint","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.108324_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108786","article-title":"Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer","volume":"209","author":"Andreas","year":"2025","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108324_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/srep15437","article-title":"Topotecan for relapsed small-cell lung cancer: systematic review and meta-analysis of 1347 patients","volume":"5","author":"Horita","year":"2015","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108324_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108324_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2026.108324_bib11","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.59125","article-title":"Clinical implications of monitoring nivolumab immunokinetics in non\u2013small cell lung cancer patients","volume":"3","author":"Osa","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.esmoop.2026.108324_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1152934","article-title":"Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: an update review","volume":"14","author":"Zhai","year":"2023","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.esmoop.2026.108324_bib13","article-title":"Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer","volume":"5","author":"Chakraborty","year":"2024","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108324_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2017.205","article-title":"Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models","volume":"117","author":"Belgiovine","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108324_bib15","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108324_bib16","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108324_bib17","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"issue":"10495","key":"10.1016\/j.esmoop.2026.108324_bib18","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.108324_bib19","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2025.43.16_suppl.8013","article-title":"Safety and efficacy of lurbinectedin plus atezolizumab as second-line treatment for advanced small-cell lung cancer: results of the 2SMALL phase 1\/2 study (NCT04253145)","volume":"43","author":"Ponce Aix","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108324_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jtho.2025.02.005","article-title":"Lurbinectedin plus pembrolizumab in relapsed SCLC: the phase I\/II LUPER study","volume":"20","author":"Calles","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108324_bib21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccell.2024.01.010","article-title":"Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade","volume":"42","author":"Nabet","year":"2024","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108324_bib22","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jtho.2023.05.008","article-title":"Clinical benefit from immunotherapy in patients with SCLC is associated with tumor capacity for antigen presentation","volume":"18","author":"Rudin","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108324_bib23","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41467-025-67078-9","article-title":"Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer","volume":"17","author":"Seo","year":"2025","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108324_bib24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:33:22Z","timestamp":1787848402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926022660"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108324","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108324","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108324"}}